Biohal

Biohal

Created using Figma
A platform to accelerate biotech breakthroughs with liquid biopsy research
ICO
Nov 15, 2018
Nov 30, 2019
100% completed
Raised funds - no Data
Cap 5 000 000.00 USD
Hard cap 550 000 000.00 USD
past
Token Details
Ticker
PON
Accepted Currencies
ETH, BTC, XRP
Company Details
Registered Country
Malta
Additional Details
Categories
Platform

About Biohal

BIOHAL OPEN NETWORK is a decentralized preventive medicine platform with liquid biopsy authentication protocol that enables secure and transparent exchange and usage of a variety of medical data.

As liquid biopsy experts, we are having an extremely difficult time to know the fact that most people recognized their cancer at stage 1 to 4, needed an emergency surgery or already cannot be cured. Our mission is to eliminate that situation and find their disease at stage 0.

BIOHAL OPEN NETWORK is a free, open-source, blockchain based biometrics authentication protocol featuring the reliable and secure architecture of Biometrics: Smart contracts that utilize liquid biopsy test as known as PROTEO.

There are international regulations on every means of transportation of infectious substances (air, rail, road and marine transport as well as mail). The UN model rules are reflected in the international laws through the international model agreements. We have invented the dried serum technology by separating serum from the blood as a way to solve these problems. This enables safe transport of dried serum. By enabling transport of dried serum, it is possible to perform a stable test whose accuracy is not adversely affected by the condition of transportation.

 

Biohal Roadmap

  • Q1 2018

  • Started decentralized medical blockchain project
  • Q2 2018

  • Started to develop Demo app with Bio medical protocol
  • Q3 2018

  • BIOHAL ICO Launched
    Bio Authentication Dapp(β)
  • Q2 2019

  • Establish the new Liquid Biopsy Labs
    Release BIOHAL Open Network(α)

Biohal Team

Verified 50%

Attention. There is a risk that unverified members are not actually members of the team

Yuki Hasegawa
CEO & Founder
verified
Kensho Yorozu
CTO
unverified

Advisors

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Raj S. Dave
Legal Advisor
unverified
Yoshitaka Fukuzawa
Medical Advisor
unverified
Akinobu Gotoh
Medical Advisor
unverified
Youichi Chikamoto
Medical Advisor
unverified

Biohal Interviews

Yuki Hasegawa
As a team member, сan you tell us about your role in the ICO project?
I am Yuki Hasegawa, CEO & Founder of Biohal.
We are working on building big data with liquid biopsy technology.
Liquid biopsy technology has been completed, now we are preparing social verification tests starting from 2019 in Japan.
What do you think about idea?
Biohal will develop a totally new ecosystem to change the existing medical system which keeps its expenses increasing and reduces its costs. And it will result to create a world without serious disease. We aim to build BIOHAL and contribute to society by reducing as much as possible any person suffering from disease by many people around the world finding disease early.
Your medical test and treatment data could help other patients, then their medical data could help more people. You could help anyone in need anywhere in the world regardless of where you are.

Biohal Last News

  • Due to potential time differences in information updates, please verify the accuracy of each ICO project through its official website or other official communication channels.
  • This information is not intended as a recommendation or suggestion for ICO investment. Please conduct thorough research on the relevant information and make your own informed decision regarding ICO participation.
  • If you identify any issues or errors in this content, or if you wish to submit your own ICO project for listing, please contact us via email at info@icoholder.com.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.